Head and neck squamous cell carcinoma
INBXInhibrx Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for INBRX-106 (OX40 agonist) + Keytruda in Head and neck squamous cell carcinoma . The expected timing is based on the latest available company guidance and may change.
05/14/26:- HNSCC interim data reiterated. Phase 2 PFS data planned in Q4 2026. 08/13/26:- Randomized Phase 2 HNSCC PFS data will be announced in Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.